Sarepta Therapeutics Q2 Earnings Call Highlights
Yahoo Finance · Aug 6, 2026 · Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics (NASDAQ:SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing
Not investment advice. Cached headline, not a full reprint.